Latest news

• First migraine prevention drug to hit European market

  The treatment seems to be off to a promising start, storming well ahead of rival treatments from Eli Lilly’s galcanezumab, Teva’s fremanezumab and Alder's eptinezumab.

• CGRP migraine drugs need prior approval for use, recommends ICER

  s fremanezumab and Eli Lilly’s galcanezumab are used prudently. ... Fremanezumab and galcanezumab remain under FDA review but should have decisions before year-end, will also be priced around the same level as Aimovig.

• ICER says price of Amgen/Novartis’ Aimovig is OK - if used last-line

  It now assumes that Teva’s fremanezumab and Eli Lilly’s galcanezumab, which remain under FDA review but should have decisions before year-end, will also be priced around the same

• Novartis, Amgen set low price for first CGRP migraine drug

  Amgen and Novartis have beaten Lilly's galcanezumab, Teva's fremanezumab and Alder's eptinezumab to market, with first-mover advantage in a market for CGRP drugs that is expected to ... Lilly is expecting the FDA to complete its review of galcanezumab in

• Amgen and Novartis migraine drug hits the mark again

  other CGRP drugs in development, a group which includes Eli Lilly's galcanezumab, Teva's fremanezumab and Alder's eptinezumab.